S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:ATEC

Alphatec - ATEC Stock Forecast, Price & News

$9.74
+0.12 (+1.25%)
(As of 08/15/2022 05:18 PM ET)
Add
Compare
Today's Range
$9.46
$9.81
50-Day Range
$6.36
$9.62
52-Week Range
$5.73
$15.31
Volume
607,860 shs
Average Volume
702,941 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.08

Alphatec MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
54.9% Upside
$15.08 Price Target
Short Interest
Bearish
9.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.43mentions of Alphatec in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.42) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

496th out of 1,125 stocks

Surgical & Medical Instruments Industry

47th out of 113 stocks

ATEC stock logo

About Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

Alphatec Stock Up 8.0 %

Shares of ATEC Stock opened at $9.62 on Monday. Alphatec has a 12-month low of $5.73 and a 12-month high of $15.31. The firm has a 50-day moving average price of $7.22 and a 200 day moving average price of $9.26. The company has a debt-to-equity ratio of 29.74, a current ratio of 2.19 and a quick ratio of 1.34.

Analysts Set New Price Targets

Several research firms recently issued reports on ATEC. The Goldman Sachs Group decreased their price objective on shares of Alphatec from $11.00 to $9.50 and set a "neutral" rating for the company in a report on Monday, August 8th. Needham & Company LLC lowered their target price on Alphatec from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Thursday, May 26th. HC Wainwright upped their price target on Alphatec from $19.00 to $20.00 in a report on Friday, May 6th. Finally, Lake Street Capital reissued a "buy" rating and issued a $9.00 price target on shares of Alphatec in a report on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.08.

Insider Activity at Alphatec

In other Alphatec news, CEO Patrick Miles sold 100,000 shares of the business's stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $8.34, for a total value of $834,000.00. Following the completion of the transaction, the chief executive officer now directly owns 5,858,634 shares of the company's stock, valued at $48,861,007.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Patrick Miles sold 100,000 shares of Alphatec stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $8.34, for a total transaction of $834,000.00. Following the completion of the sale, the chief executive officer now owns 5,858,634 shares in the company, valued at approximately $48,861,007.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Craig E. Hunsaker sold 70,000 shares of Alphatec stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $7.16, for a total transaction of $501,200.00. Following the sale, the executive vice president now owns 1,362,229 shares of the company's stock, valued at approximately $9,753,559.64. The disclosure for this sale can be found here. In the last ninety days, insiders bought 75,700 shares of company stock valued at $530,760 and sold 300,000 shares valued at $2,339,500. 33.93% of the stock is currently owned by insiders.

Receive ATEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

ATEC Stock News Headlines

Alphatec Q2 2022 Earnings Preview - Seeking Alpha
ATEC to Host Investor Day Today, May 25, 2022
See More Headlines
Receive ATEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

ATEC Company Calendar

Last Earnings
11/04/2021
Today
8/15/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATEC
CUSIP
02081G10
Employees
561
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$15.08
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+54.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-144,330,000.00
Pretax Margin
-55.82%

Debt

Sales & Book Value

Annual Sales
$243.21 million
Book Value
$0.80 per share

Miscellaneous

Free Float
69,146,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
1.62

Social Links















ATEC Stock - Frequently Asked Questions

Should I buy or sell Alphatec stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings
or view top-rated stocks.

What is Alphatec's stock price forecast for 2022?

5 Wall Street analysts have issued 12 month target prices for Alphatec's shares. Their ATEC share price forecasts range from $9.00 to $22.00. On average, they anticipate the company's share price to reach $15.08 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts price targets for ATEC
or view top-rated stocks among Wall Street analysts.

How have ATEC shares performed in 2022?

Alphatec's stock was trading at $11.43 on January 1st, 2022. Since then, ATEC stock has decreased by 15.0% and is now trading at $9.72.
View the best growth stocks for 2022 here
.

When is Alphatec's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ATEC earnings forecast
.

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) announced its quarterly earnings results on Thursday, November, 4th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20. The medical technology company earned $62.88 million during the quarter, compared to analyst estimates of $61.43 million. Alphatec had a negative trailing twelve-month return on equity of 268.17% and a negative net margin of 55.97%. During the same quarter in the prior year, the company earned ($0.18) earnings per share.

What guidance has Alphatec issued on next quarter's earnings?

Alphatec updated its FY 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325.00 million-$325.00 million, compared to the consensus revenue estimate of $316.16 million.

What is Pat Miles' approval rating as Alphatec's CEO?

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

What other stocks do shareholders of Alphatec own?

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (2.79%), Cerity Partners LLC (1.52%), Deutsche Bank AG (1.12%), King Luther Capital Management Corp (1.10%), Northern Trust Corp (0.64%) and Renaissance Technologies LLC (0.37%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David R Pelizzon, David Sponsel, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jeffrey G Black, Jeffrey P Rydin, Jennifer N Pritzker, Jennifer N Pritzker, Mortimer Berkowitz III, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends
.

How do I buy shares of Alphatec?

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $9.72.

How much money does Alphatec make?

Alphatec (NASDAQ:ATEC) has a market capitalization of $1.02 billion and generates $243.21 million in revenue each year. The medical technology company earns $-144,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Alphatec have?

The company employs 561 workers across the globe.

When was Alphatec founded?

Alphatec was founded in 1990.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The official website for the company is www.atecspine.com. The medical technology company can be reached via phone at (760) 431-9286, via email at ir@alphatecspine.com, or via fax at 800-922-1356.

This page (NASDAQ:ATEC) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.